GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » Cyclically Adjusted Price-to-FCF

Tricida (Tricida) Cyclically Adjusted Price-to-FCF : (As of May. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tricida Cyclically Adjusted Price-to-FCF?

Tricida does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Tricida Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Tricida's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tricida Cyclically Adjusted Price-to-FCF Chart

Tricida Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial - - - - -

Tricida Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tricida's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Tricida's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tricida's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tricida's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tricida's Cyclically Adjusted Price-to-FCF falls into.



Tricida Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Tricida does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.


Tricida  (OTCPK:TCDAQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Tricida Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Tricida's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tricida (Tricida) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7000 Shoreline Court, Suite 201, South San Francisco, CA, USA, 94080
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.
Executives
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert J Alpern director YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Sibling Capital Fund Ii-b L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Ii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Brian M. Isern 10 percent owner, other: *possible member of 10% group 2033 6TH AVE., SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-c L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Iii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-a L.p. 10 percent owner, other: possible member of 10% group 500 YALE AVE N, SEATTLE WA 98109
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036

Tricida (Tricida) Headlines

From GuruFocus

Tricida Announces Administrative Stop of the VALOR-CKD Trial

By GuruFocusNews GuruFocusNews 06-18-2022

Tricida Announces Administrative Stop of the VALOR-CKD Trial

By GuruFocusNews GuruFocusNews 06-28-2022

Tricida Inc (TCDA) President and CEO Gerrit Klaerner Sold $758,520 of Shares

By GuruFocus Research GuruFocus Editor 11-18-2021